1. Home
  2. OZ vs SGMT Comparison

OZ vs SGMT Comparison

Compare OZ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belpointe PREP LLC Units

OZ

Belpointe PREP LLC Units

HOLD

Current Price

$47.26

Market Cap

196.2M

Sector

N/A

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.24

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OZ
SGMT
Founded
2020
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
196.2M
169.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
OZ
SGMT
Price
$47.26
$7.24
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
5.0K
886.5K
Earning Date
05-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,187,000.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
243.44
N/A
52 Week Low
$47.26
$3.44
52 Week High
$69.00
$11.41

Technical Indicators

Market Signals
Indicator
OZ
SGMT
Relative Strength Index (RSI) 36.12 54.11
Support Level N/A $7.09
Resistance Level $51.50 $7.86
Average True Range (ATR) 0.70 0.41
MACD -0.08 -0.07
Stochastic Oscillator 23.94 57.43

Price Performance

Historical Comparison
OZ
SGMT

About OZ Belpointe PREP LLC Units

Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: